BRIEF-Aralez announces FDA approval of Yosprala for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin-associated gastric ulcers
Sept 15 (Reuters) - Aralez Pharmaceuticals Inc
* Announces FDA approval of YOSPRALA for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin associated gastric ulcers
* Aralez Pharmaceuticals Inc says YOSPRALA U.S. commercial launch planned for first week of october
* Each study achieved its individual primary endpoint
* Aralez Pharmaceuticals Inc says Aralez sales force will be expanded by 85 to 110 sales representatives by launch
* Says studies demonstrate yosprala clinical benefit Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.